AtaiBeckley
US pharmaceutical company
From Wikipedia, the free encyclopedia
AtaiBeckley Inc. is a clinical-stage biotechnology company developing treatments for mental health disorders, including therapies based on psychedelics, entactogens, and related compounds. The company was founded in November 2025 through the combination of atai Life Sciences N.V. and Beckley Psytech Limited. atai Life Sciences was founded in 2018 and became a publicly listed company in 2021.[1][2][3] Beckley Psytech, a private company, was founded in 2019.[4][5][6] In December 2025, the combined company redomiciled from the Netherlands to the U.S., incorporated in Delaware and headquartered in New York, NY.[7] The company's shares trade on the Nasdaq stock exchange under the ticker symbol ATAI.
 | |
| Type | Public |
|---|---|
| Nasdaq: ATAI | |
| Industry | Biotechnology |
| Predecessor | atai Life Sciences Beckley Psytech |
| Founded | 2018 (as atai Life Sciences) 2019 (as Beckley Psytech) 2025 (as AtaiBeckley) |
| Founder | Christian Angermayer Srinivas Rao Cosmo Feilding Mellen |
| Headquarters | , United States |
Key people | Srinivas Rao, CEO Christian Angermayer, Chairman |
| Website | www |
The company's pharmaceutical candidates include mebufotenin (5-MeO-DMT; BPL-003; intranasal) for treatment-resistant depression, dimethyltryptamine (DMT; VLS-01; oromucosal film) for treatment-resistant depression, and (R)-midomafetamine ((R)-MDMA; EMP-01) for social anxiety disorder. The company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and treatment-resistant depression.[6][8] Other previous candidates of Atai Life Sciences prior to its merger into AtaiBeckley included ibogaine (IBX-210, DMX-1002), EGX-121 (a non-tryptamine new chemical entity), psilocin (ELE-101), inidascamine (RL-007), deuterated mitragynine (KUR-101), EGX-A, EGX-B, deuterated etifoxine (GRX-917), and arketamine (PCN-101).[9][10][11]
Peter Thiel was a major investor in Atai Life Sciences before it merged into AtaiBeckley.[1] Atai Life Sciences also had a 22.4% stake in Compass Pathways.[1][2]
In July 2026, it was announced that Eli Lilly and Company, the world's largest pharmaceutical company, would acquire AtaiBeckley for US$2.8 billion.[12][13][14]